Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 4/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20512805 | 0.83 | NOS1 (0.46) | NOS1AXLMAPTTRPA1METAP2 | |
| SCHEMBL12121760 | 0.81 | HTT (0.38) | NOS1HTTPTK2MAPTTRPA1 | |
| SCHEMBL24032943 | 0.79 | AXL (0.49) | NOS1AXLMETAP2CSNK2A1DYRK1A | |
| SCHEMBL22655732 | 0.79 | NOS1 (0.42) | NOS1AXLTRPA1METAP2CSNK2A1 | |
| SCHEMBL21631684 | 0.75 | NOS1 (0.42) | NOS1AXLHTTPTK2MAPT | |
| SCHEMBL31437637 | 0.75 | MAPT (0.43) | NOS1AXLHTTPTK2MAPT | |
| SCHEMBL31433896 | 0.74 | NOS1 (0.40) | NOS1AXLMAPTTRPA1METAP2 | |
| SCHEMBL2425031 | 0.73 | NOS1 (0.52) | NOS1AXLMAPTTRPA1METAP2 | |
| SCHEMBL15288493 | 0.72 | NOS1 (0.55) | NOS1AXLHTTPTK2MAPT | |
| SCHEMBL14500106 | 0.72 | NOS1 (0.50) | NOS1AXLHTTPTK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| EP-4441042-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118748995-A | 5-Pyrimidine carboxamide derivatives and methods of use thereof | 亚根达医疗公司 | 2024-10-08 | — | — | CN | disclosed |
| WO-2023102231-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RTCB, NSUN2, PRPF19 | NOS1 2322/4885AXL 3243/4885HTT 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.